Targeted Therapies for Cutaneous Melanoma

被引：13

作者：

Kee, Damien ^{[1
,2
]}

McArthur, Grant ^{[1
,2
,3
]}

机构：

[1] Peter MacCallum Canc Ctr, Div Canc Med & Res, East Melbourne, Vic 3002, Australia

[2] Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia

[3] Univ Melbourne, Dept Med, St Vincent Hosp, Fitzroy, Vic 3065, Australia

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2014年 / 28卷 / 03期

关键词：

Melanoma; Targeted therapy; MAPK signaling; BRAF; MEK; NRAS; MULTIKINASE INHIBITOR SORAFENIB; MUTATION-POSITIVE MELANOMA; PHASE-III TRIAL; METASTATIC MELANOMA; OPEN-LABEL; BRAIN METASTASES; RAF INHIBITORS; MUTANT MELANOMA; CEREBRAL METASTASES; MEK1/2; INHIBITOR;

D O I：

10.1016/j.hoc.2014.02.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Melanoma is resistant to cytotoxic therapy, and treatment options for advanced disease have been limited historically. However, improved understanding of melanoma driver mutations, particularly those involving the mitogen-activated protein kinase pathway, has led to the development of targeted therapies that are effective in this previously treatment-refractory disease. In cutaneous melanomas with BRAF V600 mutations the selective RAF inhibitors, vemurafenib and dabrafenib, and the MEK inhibitor, trametinib, have demonstrated survival benefits. Early signals of efficacy have also been demonstrated with MEK inhibitors in melanomas with NRAS mutations, and KIT inhibitors offer promise in melanomas driven through activation of their target receptor.

引用

页码：491 / 505

页数：15

共 88 条

[1] Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study [J].

Agarwala, SS ;

Kirkwood, JM ;

Gore, M ;

Dreno, B ;

Thatcher, N ;

Czarnetski, B ;

Atkins, M ;

Buzaid, A ;

Skarlos, D ;

Rankin, EM .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2101-2107

[2] Multisite Analytic Performance Studies of a Real-Time Polymerase Chain Reaction Assay for the Detection of BRAF V600E Mutations in Formalin-Fixed, Paraffin-Embedded Tissue Specimens of Malignant Melanoma [J].

Anderson, Steven ;

Bloom, Kenneth J. ;

Vallera, Dino U. ;

Rueschoff, Josef ;

Meldrum, Cliff ;

Schilling, Robert ;

Kovach, Barbara ;

Lee, Ju Ruey-Jiuan ;

Ochoa, Pam ;

Langland, Rachel ;

Halait, Harkanwal ;

Lawrence, H. Jeffrey ;

Dugan, Michael C. .

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (11) :1385-1391

[3] BRAF Inhibitor-Driven Tumor Proliferation in a KRAS-Mutated Colon Carcinoma Is Not Overcome by MEK1/2 Inhibition [J].

Andrews, Miles C. ;

Behren, Andreas ;

Chionh, Fiona ;

Mariadason, John ;

Vella, Laura J. ;

Do, Hongdo ;

Dobrovic, Alexander ;

Tebbutt, Niall ;

Cebon, Jonathan .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (35) :E448-E451

[4] Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma [J].

Ascierto, Paolo A. ;

Minor, David ;

Ribas, Antoni ;

Lebbe, Celeste ;

O'Hagan, Anne ;

Arya, Niki ;

Guckert, Mary ;

Schadendorf, Dirk ;

Kefford, Richard F. ;

Grob, Jean-Jacques ;

Hamid, Omid ;

Amaravadi, Ravi ;

Simeone, Ester ;

Wilhelm, Tabea ;

Kim, Kevin B. ;

Long, Georgina V. ;

Martin, Anne-Marie ;

Mazumdar, Jolly ;

Goodman, Vicki L. ;

Trefzer, Uwe .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26) :3205-+

[5] MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study [J].

Ascierto, Paolo A. ;

Schadendorf, Dirk ;

Berking, Carola ;

Agarwala, Sanjiv S. ;

van Herpen, Carla M. L. ;

Queirolo, Paola ;

Blank, Christian U. ;

Hauschild, Axel ;

Beck, J. Thaddeus ;

St-Pierre, Annie ;

Niazi, Faiz ;

Wandel, Simon ;

Peters, Malte ;

Zubel, Angela ;

Dummer, Reinhard .

LANCET ONCOLOGY, 2013, 14 (03) :249-256

[6] Final Version of 2009 AJCC Melanoma Staging and Classification [J].

Balch, Charles M. ;

Gershenwald, Jeffrey E. ;

Soong, Seng-jaw ;

Thompson, John F. ;

Atkins, Michael B. ;

Byrd, David R. ;

Buzaid, Antonio C. ;

Cochran, Alistair J. ;

Coit, Daniel G. ;

Ding, Shouluan ;

Eggermont, Alexander M. ;

Flaherty, Keith T. ;

Gimotty, Phyllis A. ;

Kirkwood, John M. ;

McMasters, Kelly M. ;

Mihm, Martin C., Jr. ;

Morton, Donald L. ;

Ross, Merrick I. ;

Sober, Arthur J. ;

Sondak, Vernon K. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6199-6206

[7] KIT Gene Mutations and Copy Number in Melanoma Subtypes [J].

Beadling, Carol ;

Jacobson-Dunlop, Erick ;

Hodi, F. Stephen ;

Le, Claudia ;

Warrick, Andrea ;

Patterson, Janice ;

Town, Ajia ;

Harlow, Amy ;

Cruz, Frank, III ;

Azar, Sharl ;

Rubin, Brian P. ;

Muller, Susan ;

West, Rob ;

Heinrich, Michael C. ;

Corless, Christopher L. .

CLINICAL CANCER RESEARCH, 2008, 14 (21) :6821-6828

[8] Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma [J].

Bollag, Gideon ;

Hirth, Peter ;

Tsai, James ;

Zhang, Jiazhong ;

Ibrahim, Prabha N. ;

Cho, Hanna ;

Spevak, Wayne ;

Zhang, Chao ;

Zhang, Ying ;

Habets, Gaston ;

Burton, ElizabethA. ;

Wong, Bernice ;

Tsang, Garson ;

West, Brian L. ;

Powell, Ben ;

Shellooe, Rafe ;

Marimuthu, Adhirai ;

Nguyen, Hoa ;

Zhang, Kam Y. J. ;

Artis, Dean R. ;

Schlessinger, Joseph ;

Su, Fei ;

Higgins, Brian ;

Iyer, Raman ;

D'Andrea, Kurt ;

Koehler, Astrid ;

Stumm, Michael ;

Lin, Paul S. ;

Lee, Richard J. ;

Grippo, Joseph ;

Puzanov, Igor ;

Kim, Kevin B. ;

Ribas, Antoni ;

McArthur, Grant A. ;

Sosman, Jeffrey A. ;

Chapman, Paul B. ;

Flaherty, Keith T. ;

Xu, Xiaowei ;

Nathanson, Katherine L. ;

Nolop, Keith .

NATURE, 2010, 467 (7315) :596-599

[9] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[10] The Discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors [J].

Buckmelter, Alex J. ;

Ren, Li ;

Laird, Ellen R. ;

Rast, Bryson ;

Miknis, Greg ;

Wenglowsky, Steve ;

Schlachter, Stephen ;

Welch, Mike ;

Tarlton, Eugene ;

Grina, Jonas ;

Lyssikatos, Joseph ;

Brandhuber, Barbara J. ;

Morales, Tony ;

Randolph, Nikole ;

Vigers, Guy ;

Martinson, Matthew ;

Callejo, Michele .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (04) :1248-1252

← 1 2 3 4 5 6 7 8 9 →